



AstraZeneca Pharma India Limited

CIN: L24231KA1979PLC003563

Regd. Office: Block N1, 12th Floor, Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road, Bangalore - 560 045.

Tel.: +91 80 6774 8000. Web: www.astrazeneca.com/india

Statement of unaudited financial results for the quarter and nine months ended 31 December 2019

Rs in lakhs except for earnings per share data

Sl. No.	Particulars	3 months ended 31/12/2019	Year to date figure for current period ended 31/12/2019	Corresponding 3 months ended in the previous year 31/12/2018
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total income from operations	22,732.43	64,651.87	21,868.97
2	Net profit / (loss) for the period from ordinary activities before tax	3,518.26	10,060.78	4,059.46
3	Net profit / (loss) for the period from ordinary activities after tax	2,670.17	6,263.23	2,909.18
4	Total comprehensive income for the period after tax	2,750.43	6,000.10	2,869.72
5	Equity Share Capital	500.00	500.00	500.00
6	Reserves (excluding revaluation reserves as per balance sheet)*	-	-	-
7	Basic and diluted earnings per share (of Rs 2 each)	10.68	25.05	11.64

*Reserves excluding revaluation reserves for the year ended 31 March 2019 was Rs. 29,580 lakhs as per audited financials statements

Note:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites (www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).
- The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited
Gagandeep Singh Bedi
Managing Director

Place: Bangalore
Date: 03-02-2020

